In an 8 week randomized, double blind, placebo controlled trial, Weizmannia coagulans BC99 demonstrated significant clinical and immunological benefits in children with allergic rhinitis. Daily supplementation (2 × 10⁹ CFU) led to marked improvements in symptom control and quality of life, as reflected by reduced RCAT and RQLQ scores versus placebo. These clinical effects were accompanied by a clear shift in immune balance, with reductions in serum IgE, Th2 cytokines (IL 4, IL 13), TNF α, and eosinophils, alongside an increase in IFN γ and the IFN γ/IL 4 ratio, indicating restoration of Th1, Th2 homeostasis. Mechanistically, BC99 modulated the gut microbiota by enriching beneficial SCFA producing genera such as Bifidobacterium and Roseburia while suppressing pro inflammatory taxa including Escherichia Shigella. This microbial remodeling translated into higher fecal levels of key short chain fatty acids, notably acetic and butyric acid, which correlated positively with anti inflammatory immune markers. Functional predictions further suggested activation of metabolic pathways linked to immune regulation, including PPAR signaling. BC99 was well tolerated with no adverse events, supporting its role as a probiotic driven, gut microbiota SCFA immune axis modulator for managing pediatric allergic rhinitis.
Source : linkinghub.elsevier.com/retrieve/pii/S1567576925017758
